Trials / Not Yet Recruiting
Not Yet RecruitingNCT06972589
The Effect of Mask Design on Ventilation Parameters in COPD and OHS Patients on Long-term Home Non-invasive Ventilation. An Experimental Study.
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Fisher and Paykel Healthcare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Chronic obstructive pulmonary disease (COPD) and obesity hypoventilation syndrome (OHS) are respiratory conditions that disrupt normal breathing. Positive airway pressure, specifically Non-Invasive Ventilation (NIV) delivers positive pressures via an interface such as a face mask and has been shown to improve breathing and reduce symptoms in patients with these conditions. Regular use of NIV can lead to better symptom management, improved quality of life, and reduced use of healthcare resources. However, poor performance of the NIV mask and poor comfort can make NIV therapy harder to tolerate. This study will assess if a new mask helps to improve the breathing of people on NIV and normalize blood gases.
Detailed description
Participants are moved to the sleep laboratory for the night where they are provided with beds. * The participants are put on their prescribed airway pressure support with the first randomized mask. * After at least 60 minutes of recording, participants are awakened to switch back to the second mask. They are then allowed to sleep uninterrupted for the rest of the night.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Investigational Mask | Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy during sleep. |
| DEVICE | Conventional mask | Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy during sleep. |
Timeline
- Start date
- 2025-05-01
- Primary completion
- 2026-04-01
- Completion
- 2026-04-01
- First posted
- 2025-05-15
- Last updated
- 2025-05-15
Locations
1 site across 1 country: New Zealand
Source: ClinicalTrials.gov record NCT06972589. Inclusion in this directory is not an endorsement.